When was WuXi AppTec founded?

WuXi AppTec was founded in 2000 and raised its 1st funding round 7 years after it was founded.

Where is WuXi AppTec located?

WuXi AppTec is headquartered in Shanghai, China. It is registered at Saint Paul, Minnesota.

How many employees does WuXi AppTec have?

As of Nov 16, 2025, the latest employee count at WuXi AppTec is 4155.

Is WuXi AppTec a funded company?

WuXi AppTec is a funded company, having raised a total of $40M across 5 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Feb 2007.

When was the latest funding round of WuXi AppTec?

WuXi AppTec's latest funding was a $***** Post IPO round on Apr 02, 2021, with participation from 1 investor.

What is the annual revenue of WuXi AppTec?

Annual revenue of WuXi AppTec is £7.42M as on Dec 31, 2024.

Where does WuXi AppTec rank among its competitors?

WuXi AppTec ranks 2nd amongst 1028 active competitors, of which 64 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Ipsen, which secured $618K in Dec, 2023.

Who are the top competitors of WuXi AppTec?

WuXi AppTec's top competitors include Precision Medicine Group, ANI Pharmaceuticals and Aptar. Among them, Ipsen secured the most recent funding round in December, 2023.

WuXi AppTec - 2026 Company Profile, Team, Funding, Competitors & Financials

WuXi AppTec is a public company based in Shanghai (China), founded in 2000. It operates as a Provider of CRO and CDMO services. WuXi AppTec has raised $40M in funding. The company has 1028 active competitors, including 64 funded and 123 that have exited. Its top competitors include companies like Precision Medicine Group, ANI Pharmaceuticals and Aptar.

Company Details

WuXi AppTec is a provider of a suite of CRO and CDMO services for small molecules, biologics, and medical devices. It offers a suite of services for the research, development, and manufacturing of both small molecules and biologics and also caters to medical device development and has operations all over the globe. They provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. The company built its initial capabilities around discovery chemistry and has further enhanced the integrated services with analytical services, bio-analytical services, process research, process development services, API manufacturing services, DMPK/ADME, discovery biology, pharmacology, formulation, toxicology, genomic services, biologics manufacturing services, antibody, and biological research reagent manufacturing and sales, and most recently clinical research and regulatory services. In 2022, the company recorded annual revenues of $5.84B and a net profit of $1.31B.

Website: wuxiapptec.com
Social
Registered Address: Saint Paul, Minnesota

Key Metrics

Founded Year

2000

Location

Shanghai, China

Stage

Public

Total Funding

$40M in 5 rounds

Latest Funding Round

Post IPO, Apr 02, 2021, $*****

Investors

Strait Huifu Industrial Investment Fund Management & 28 more

Ranked

2^nd among 1028 active competitors

Annual Revenue

£7.42M as on Dec 31, 2024

Employee Count

4,155 as on Nov 16, 2025

Investment & Acquisitions

D3 Bio & 47 more

Similar Companies

Precision Medicine Group & 1072 more

Exit Details

Public

View WuXi AppTec's full profile

WuXi AppTec is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
WUXI APP TEC, INC. CIN: 300135172 , United States, Active	Dec 31, 1999	-	1733 (As on Dec 31, 2024)	-
WUXI APPTEC UK LTD CIN: 7495313 , United Kingdom, Active	Jan 16, 2011	$9.48M (As on Dec 31, 2024)	33 (As on Dec 31, 2024)

WuXi AppTec got listed on Dec 14, 2018.

Click here to take a look at WuXi AppTec's IPO in detail

WuXi AppTec has raised a total funding of $40M over 5 rounds. Its first funding round was on Feb 2007. Its latest funding round was a Post IPO round on Apr 02, 2021 for $*****. 1 investor participated in its latest round. WuXi AppTec has 29 institutional investors.

Here is the list of recent funding rounds of WuXi AppTec:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 02, 2021	6011284	Post IPO	8327074	6636430	5316972	9634101
Aug 24, 2020	1627358	Post IPO	7801722	4628848	2025949	1769234
Mar 02, 2016	5649470	Conventional Debt	8863487	6335460	1463653	Ping An Bank

Access funding benchmarks and valuations. Sign up today!

View details of WuXi AppTec's funding rounds and investors

WuXi AppTec's employee count trend

WuXi AppTec has 4,155 employees as of Nov 25. Here is WuXi AppTec's employee count trend over the years:

Uncover WuXi AppTec's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of WuXi AppTec include Precision Medicine Group, ANI Pharmaceuticals and Aptar. Here is the list of Top 10 competitors of WuXi AppTec, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Precision Medicine Group 2012, Bethesda (United States), Late Stage	Provider of clinical research, development, and commercialization services for life sciences	$532M	TPG, Oak Investment Partners & 7 others	71/100
2nd	WuXi AppTec 2000, Shanghai (China), Public	Provider of CRO and CDMO services	$40M	Strait Huifu Industrial Investment Fund Management, HPR Capital ... & 27 others	79/100
3rd	ANI Pharmaceuticals 1996, Baudette (United States), Public	Pharmaceutical company developing, manufacturing, and marketing high quality branded and generic prescription drugs	-	US Bank, Ampersand Capital & 4 others	63/100
4th	Aptar 1992, Crystal Lake (United States), Public	Provider of regulatory support, brand differentiation, and prototyping services	-	Al Zayani Investments	63/100
5th	Avania 1988, Brunswick (Australia), Acquired	Provider of regulatory, clinical trials and analytic services	-	Kester Capital, Omnes Capital & 1 others	63/100
6th	Eurofins Scientific 1987, Luxembourg (Luxembourg), Public	Provider of laboratory testing services and CRO contract research services	-	CDPQ, Holland Capital & 1 others	57/100
7th	Red Nucleus 2014, Yardley (United States), Acquired	Provider of advisory, scientific and medical communications for pharmaceutical industry	-	Maranon Capital, Renovus Capital Partners	57/100
8th	Ipsen 1929, Paris (France), Public	Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes	-	Digital Pharma Lab, PAI Partners & 2 others	57/100
9th	CHEPLAPHARM 1998, Mesekenhagen (Germany), Late Stage	Pharmaceutical company that specializes in the development, marketing, and distribution of branded pharmaceutical products	$547M	GIC, Atlantic Park & 4 others	56/100
10th	Isolere Bio 2017, Durham (United States), Acquired	Developer of bioprocessing reagents for purification and manufacturing of therapeutics	$7M	Northpond Ventures, NCBiotech & 2 others	56/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on WuXi AppTec's competitors? Click here to see the top ones

WuXi AppTec has made 39 investments in companies including D3 Bio and Structure. WuXi AppTec has also acquired 9 companies including OXGENE and Mingjie Pharmaceutical.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Apr 08, 2024	Investments	D3 Bio	2018	Shanghai (China)
Oct 20, 2021	Investments	Structure	2017	San Francisco (United States)
Jun 03, 2021	Investments	Siwei Biotechnology	2016	Pudong (China)